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Abstract
Background:  The S100 protein family comprises 22 members whose protein sequences
encompass at least one EF-hand Ca2+ binding motif. They were involved in the regulation of a
number of cellular processes such as cell cycle progression and differentiation. However, the
expression status of S100 family members in gastric cancer was not known yet.
Methods: Combined with analysis of series analysis of gene expression, virtual Northern blot and
microarray data, the expression levels of S100 family members in normal and malignant stomach
tissues were systematically investigated. The expression of S100A3 was further evaluated by
quantitative RT-PCR.
Results: At least 5 S100 genes were found to be upregulated in gastric cance by in silico analysis.
Among them, four genes, including S100A2, S100A4, S100A7 and S100A10, were reported to
overexpressed in gastric cancer previously. The expression of S100A3 in eighty patients of gastric
cancer was further examined. The results showed that the mean expression levels of S100A3 in
gastric cancer tissues were 2.5 times as high as in adjacent non-tumorous tissues. S100A3
expression was correlated with tumor differentiation and TNM (Tumor-Node-Metastasis) stage of
gastric cancer, which was relatively highly expressed in poorly differentiated and advanced gastric
cancer tissues (P < 0.05).
Conclusion: To our knowledge this is the first report of systematic evaluation of S100 gene
expressions in gastric cancers by multiple in silico analysis. The results indicated that
overexpression of S100 gene family members were characteristics of gastric cancers and S100A3
might play important roles in differentiation and progression of gastric cancer.
Background
Gastric cancer is the second most common cause of cancer
death worldwide. Environmental and genetic factors are
both important in gastric carcinogenesis [1,2]. In the past
two decades, much progress has been made in identifying
genes involved in the development of gastric cancer. These
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identified genes are useful in understanding the patho-
genesis of gastric cancer and defining its molecular signa-
ture. They can also serve as biomarkers for early diagnosis
and targets for drug development.
Recently, large-scale gene expression analyses have
emerged as important tools for screening genes related to
cancer [3]. The two experimental technologies available
for large-scale gene expression analysis are: 1) DNA
sequencing-based serial analysis of gene expression
(SAGE) and expressed sequence tag (EST) approaches and
2) dot-blot based microarray analysis. Multiple bioinfor-
matics infrastructures have been established to compile
data derived from these techniques. Among them, the
Cancer Genome Anatomy Project (CGAP) and Gene
Expression Omnibus (GEO) are two important net-
works[4,5]. Previous applications of data mining using
CGAP and GEO resource have led to the identification of
several novel or known cancer-related genes [6,7].
The S100 protein family comprises 22 members whose
protein sequences encompass at least one EF-hand Ca2+
binding motif[8]. S100 proteins are localized in the cyto-
plasm and/or nucleus of a wide range of cells, and
involved in the regulation of a number of cellular proc-
esses such as cell cycle progression and differentiation.
Seventeen S100 family members are located as a cluster
on chromosome 1q21–22, a region frequently rearranged
in several tumors. In addition, molecular analysis has
revealed that several S100s, including S100A2, S100A4,
S100A7 and S100A10, exhibit altered expression levels in
gastric cancer[9,10]. So it is interesting to systematically
investigate the expression of other members of S100 fam-
ily in normal and gastric cancer tissues.
In this study, we utilized the databases and analytical
approaches available from the Gene Expression Omnibus
and Cancer Genome Anatomy Project to systematically
analyze the expression of 22 S100 genes in normal and
cancerous stomach tissues. The independent SAGE and
microarray datasets were screened for S100 gene expres-
sion patterns. We provided evidence that at least five S100
genes were upregulated in gastric cancer and further exper-
imentally verified the upregulation of S100A3 by quanti-
tative RT-PCR.
Methods
SAGE analysis
SAGE measures the number of tags that represent the tran-
scriptional products of a gene. The data produced by
SAGE technology is a list of tags with their corresponding
count values. All publicly available SAGE data collected in
GEO website up to January 2008 were used for analysis of
S100 gene expression. Both NlaIII and Sau3A tags from
SAGEmap http://www.ncbi.nlm.nih.gov/SAGE/ were
mapped to UniGene clusters http://
www.ncbi.nlm.nih.gov/UniGene/. The reliable UniGene
clusters matched to S100 tags were adopted. These
sequence tags were then used to determine the levels of
expression of 22 S100 genes in 2 normal and 8 gastric can-
cer libraries. A list of the tags used for analysis was pro-
vided in Table 1 and detailed information about these
libraries are available from the GEO website. Analyses
were performed by comparing the average number of
S100 tags in libraries of normal mucosa with that in
libraries of gastric cancer. Difference of >3-fold change
will be considered as positive.
Virtual Northern
In the CGAP database, virtual Northern blot analysis ena-
bles researchers to view the expression of a specific gene in
all EST and SAGE libraries[4]. Through the Gene Finder
tool http://cgap.nci.nih.gov/Genes/GeneFinder, some
organized information about a particular gene can be
found by querying either the unique gene identifier or a
key word. Included in the available information are the
EST and SAGE vNorthern expressional patterns across all
available libraries classified according to their tissue ori-
gins. The SAGE data collected in CGAP include 5 tissue
libraries and 2 xenograft libraries of gastric cancer, as well
Table 1: SAGE analysis of S100 genes expression in normal and gastric cancer libraries
Gene name Unigene cluster SAGE tag Normal (tpm*) Cancer (tpm*)
S100A2 516484 GATCTCTTGG 0.0 98.1
S100A3 433168 TCTCCCACAC 0.0 2.8
S100A4 81256 ATGTGTAACG 0.0 207.8
S100A6 275243 CCCCCTGGAT 245.9 865.9
S100A7 112408 GAGCAGCGCC 0.0 143.8
S100A8 416073 TACCTGCAGA 0.0 549.2
S100A9 112405 GTGGCCACGG 0.0 637.0
S100A10 143873 AGCAGATCAG 263.6 1890.5
S100A12 19413 GATTTTTAAA 0.0 13.9
S100A16 515714 AGCAGGAGCA 0.0 130.6
Only S100s that show positive matches are shown in this table. *tags per million;BMC Cancer 2008, 8:261 http://www.biomedcentral.com/1471-2407/8/261
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as 3 normal libraries of stomach, which were partially dif-
ferent from that collected in GEO mentioned above. S100
genes whose expression in EST and SAGE libraries of gas-
tric cancer was both >3 fold as much as those in normal
stomach were designated as positive ones.
Microarray analysis
At present, five microarray datasets (Table 2) containing
data from normal and gastric cancer tissues were available
in GEO website http://www.ncbi.nlm.nih.gov/projects/
geo/. The dataset GSE2669, GSE2701 and GSE3438 con-
tributed by Boussioutas A[11], Chen X[12] and Kim S[13]
respectively were chosen for conducting microarray anal-
ysis because these three datasets contained relatively more
cases of normal and gastric cancer (10 normal ones and
64 cancers for Boussioutas A et al; 22 normal ones and 90
cancers for Chen X; 50 normal ones and 50 cancers for
Kim S). More details about the samples and microarray
analysis can be found from the GEO website. Difference
was considered significant when p  < 0.05. S100 genes
whose expression was both highly in three groups of gas-
tric cancer tissues were designated as positive ones.
Tissue Collection
Eighty patients with gastric cancer who underwent surgery
in our hospital from September of 2004 to March of 2007
were enrolled in this study. The resected tumor and adja-
cent non-tumorous tissue specimens were immediately
frozen in liquid nitrogen and kept at 70°C until RNA
extraction. The diagnosis of both gastric cancer and nor-
mal gastric mucosa was clinically and pathologically
proved. The patient's sex, age, tumor size, TNM stage,
depth of wall invasion, microscopic subtype, and status of
lymph node metastasis were obtained from surgical and
pathological records. The protocols used in this study
were approved by the Hospital's Protection of Human
Subjects Committee. Patients providing fresh surgical tis-
sue for the study signed informed consent.
Quantitative RT-PCR
Total RNA (mRNA) was extracted from gastric cancer and
adjacent non-tumorous tissues according to the manufac-
turer's recommendations of TRIzol reagent (Invitrogen,
Carlsbad, CA). 1 μg sample of total RNA was reverse tran-
scribed to complementary DNA (cDNA) with oligo (dT)
primers. The sense and antisense primers for S100A3 were
designed according to the mRNA sequence (GenBank
accession number NM_002960.1). We used amplified
PCR fragments spanning different exons to prevent ampli-
fication of contaminated genomic DNA. The sense primer
was 5'-GACCATCTGGTTCAGGTTCC-3' and the antisense
primer was 5'-ACATTCCCGAAACTCAGTCG-3'. The PCR
products were 200 bp in size. The housekeeping gene
GAPDH was used as an internal control. The sense primer
was 5'-CCAGGTGGTCTCCTCTGACTT-3' and the anti-
sense primer was 5'-GTTGCTGTAGCCAAATTCGTTGT-3'.
The PCR products were 130 bp in size.
The standard curve was produced by measuring the cross-
ing-point of each standard value (6-fold serially diluted
cDNAs of cardiac muscle, in which the content of S100A3
was relatively abundant) and plotting them against the
logarithmic value of the concentrations. Standard curve
samples were included in each run. Quantitative real-time
RT-PCR was performed using an ABI PRISM 7000
sequence detection system (Applied Biosystems, Foster
City, CA). The RT-PCR was carried out in a total volume
of 30 μL. The reaction mixture included 1× buffer, 200
μmol/L of deoxy-ribonucleoside triphosphates (dNTPs)
(Invitrogen), 0.3 μmol/L of sense and antisense primers,
1 U of Takara ExTaq Hotstart Taq (TaKaRa Biotechnol-
ogy), 0.6 μL of 5-carboxy-x-rhodamine (ROX) reference
dye, and 2 μL of cDNA. The PCR cycle involved 2 minutes
at 95°C followed by 40 amplification cycles of denatura-
tion at 94°C for 30 seconds, annealing at 58°C (for detec-
tion of GAPDH) or 55°C (for detection of S100A3) for 30
seconds, and elongation at 72°C for 1 minute. The rela-
tive quantitation of both S100A3 and GAPDH was deter-
mined by the comparative CT (thermal cycle) method.
The values of S100A3 mRNA expression were normalized
according to the expression of GAPDH. Each assay was
repeated three times to verify the results, and the ratio of
mRNA expression value of gastric cancer tissues to adja-
cent non-tumorous tissues was used for subsequent anal-
ysis.
Statistical analysis
For continuous variables, the data were expressed as the
means+/-SD. Expression data of S100 genes in microarray
datasets was retrieved and the differences in expression
Table 2: Microarray datasets of gastric cancer collected in Gene Expression Omnibus website.
Cases Array Spot Supplier
Normal Cancer
GSE2637 3 55 cDNA 13 k/17 K Aggarwal A et al
GSE2685 8 22 Oligo- nucleotide ~7.2 K Hippo Y et al
GSE2669 10 64 cDNA ~7.4 K Boussioutas A et al
GSE2701 22 90 cDNA 44 K Chen X et al
GSE3438 50 50 cDNA 14 K Kim S et alBMC Cancer 2008, 8:261 http://www.biomedcentral.com/1471-2407/8/261
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levels between normal and gastric cancer tissues were
determined by student T test. The association between rel-
ative expression ratios of S100A3 and clinical features was
analyzed by Mann-Whitney test. All data were analyzed
using the SPSS11.0 software package (SPSS, Chicago,
USA) and the difference was considered significant when
p < 0.05.
Results
1. SAGE and virtual Northern blot analysis of S100 genes 
expression in gastric cancer
There are 2 SAGE libraries of normal gastric mucosa and 8
SAGE libraries of gastric cancer tissues available in GEO
website (GSE545 and GSE14). These libraries were pro-
vided by two different labs [14,15]. The reliable tags of 20
S100 genes were extracted from SAGEmap website and
used to search the SAGE data. 10 genes were found to be
highly expressed in gastric cancer tissues according to the
setting criteria of >3-fold difference (Table 1). In these 10
genes, only S100A6 and S100A10 could be detectable in
normal gastric mucosa tissues, which also had top average
density in gastric cancer (865.9 tpm and 1890.5 tpm
respectively). The other 8 genes, including S100A2,
S100A3, S100A4, S100A7, S100A8, S100A9, S100A12
and S100A16, had different average density ranging from
2.8 tpm to 637.0 tpm, none of which were expressed in
normal gastric mucosa tissues. No significant difference in
expression between normal and cancerous tissues could
be found on S100A11, S100A14 and S100P (data not
shown). We then used virtual Northern blot to analyze the
expression of S100 genes (Table 3). Six genes were con-
firmed to be upregulated in gastric cancer tissues. The pos-
itive S100A6, S100A8, and S100A16 identified by SAGE
analysis were shown to have no significant difference in
expression between normal and gastric cancer libraries
when conducting EST virtual Northern Blot. S100A13, not
detectable in SAGE libraries, was shown to be highly
expressed in gastric cancer tissues by EST virtual Northern
blot. S100A3 and S100A12 could not be detected by vir-
tual Northern blot.
2. Microarray analysis of S100 genes expression in gastric 
cancer
Microarray analysis was conducted to further verify the
overexpression of S100 genes in gastric cancer. 8, 11 and
7 S100 genes could be found in GSE2669, GSE2701 and
GSE3438 datasets respectively (Table 4). Both S100A2
and S100A10 genes were shown to be upregulated in gas-
tric cancer of all three datasets. S100A3 was demonstrated
to be overexpressed in gastric cancer by dataset GSE2669
and GSE2701, which did not existed in dataset GSE3438.
S100A4, S100A6 and S100A7 were shown to be upregu-
lated in gastric cancer in only one dataset but did not exist
in the other two datasets. However, expression of S100A8
and S100A9 had no significant difference between normal
and cancerous tissues in dataset GSE2701. The differential
expression tendency of S100A12 in GSE2701 was contrary
to that of SAGE analysis (Table 1).
Taken together, 5 genes were demonstrated to be highly
expressed in gastric cancer by all three in silico analysis
approaches. They were S100A2, S100A3, S100A4, S100A7
and S100A10. Among these 5 genes, S100A3 was the only
one which was not yet reported to be related to gastric can-
cer previously. Next we evaluated the expression of
S100A3 in gastric cancer tissues by quantitative RT-PCR.
3. Verification of S100A3 overexpression in gastric cancer 
by quantitative RT-PCR
To investigate whether S100A3 was overexpressed in gas-
tric cancer, we examined the mRNA expression of S100A3
in gastric cancer tissues and corresponding adjacent non-
tumorous tissues of 80 patients by quantitative RT-PCR.
The relatively mean expression level of S100A3 in gastric
cancer was 2.52 ± 1.45 when compared to adjacent non-
tumorous tissues (p  = 0.01). Correlations of S100A3
mRNA expressions with the clinical features were further
analyzed. The results showed that S100A3 mRNA expres-
sion did not correlated with gender, age, tumor size, depth
of wall invasion, microscopic subtypes or lymph node
metastasis with a statistic p > 0.05 in each parameter
(Table 5). However, we found that the expression of
S100A3 mRNA was correlated with tumor differentiation
and Tumor-Node-Metastasis stage. The S100A3 expres-
sion levels in well- and moderate-differentiated tumor tis-
sues were both significantly lower than that in poorly
differentiated ones (p < 0.05). S100A3 expression in TNM
stage I and II was also lower than that in stage III and IV
(p = 0.04). All these data demonstrated that S100A3 was
overexpressed in gastric cancer specimens and might be
related to the differentiation and development of gastric
cancer.
Table 3: Virtual Northern blot analysis of S100 genes expression 
in normal and gastric cancer libraries
EST tags (tpm*) SAGE tags (tpm*)
Normal Cancer Normal Cancer
S100A2 0.0 25.9 0.0 200.5
S100A3 0.0 0.0 0.0 0.0
S100A4 52.3 293.7 0.0 168.4
S100A7 0.0 0.0 0.0 304.8
S100A9 0.0 8.6 0.0 1339.4
S100A10 0.0 181.4 272.3 1483.7
S100A12 0 0 0 0
S100A13 0.0 43.2 0.0 0.0
Only S100s that show positive matches are shown in this table. *tags 
per million;BMC Cancer 2008, 8:261 http://www.biomedcentral.com/1471-2407/8/261
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Discussion
Although S100 family members have a common structure
and are mainly localized in a specific region of chromo-
some 1, they all have very unique expression patterns in
normal or pathological tissues. We systematically investi-
gated the expression of S100 family members in gastric
cancer tissues by combining analysis of SAGE, virtual
Northern blot and microarray data. It has been reported
that cross-hybridization errors may happen in microarray
analysis when sequence similarity exceeds 75%. However,
the mRNA sequence similarity of S100 family members
was 4%–67%, so the possibility of cross-hybridization of
S100 genes on all the three chips analyzed in the present
study would be relatively small. Furthermore, Both SAGE
Table 4: Microarray analysis of S100 genes expression in normal and gastric cancer tissues
GSE3438 GSE2669 GSE2701
Normal* Cancer* p Normal* Cancer* p Normal* Cancer* P
S100A2 -0.22 0.00 0.00 1.03 1.35 0.01 -0.95 -0.36 0.00
S100A3 # # # 0.84 1.55 0.03 -0.14 0.05 0.03
S100A4 -0.23 0.30 0.00 # # # # # #
S100A6 -0.43 0.27 0.00 # # # # # #
S100A7 # # # # # # -1.00 -0.35 0.00
S100A8 # # # 0.32 0.69 0.01 0.66 0.70 0.81
S100A9 # # # 1.25 3.48 0.00 0.42 0.79 0.13
S100A10 -0.50 0.42 0.00 0.46 1.36 0.00 0.19 1.22 0.00
S100A12 # # # # # # 0.50 0.21 0.01
Only S100s that show positive matches are shown in the table. *data extracted from microarray datasets; # data not exist in the dataset.
Table 5: Correlation of S100A3 mRNA expression with clinicalpathological parameters in patients with gastric carcinoma.
Variable mRNA expression P
Number N/T >4 N/T 2–4 N/T 1–2 N/T <1
Gender
Male 61 11 34 9 8 0.17
F e m a l e 1 9 35 82
Age (y)
<65 54 10 31 6 7 0.08
>65 26 4 8 11 3
Tumor differentiation
Well1 3 0 0 1 2 0.22a
Moderate2 33 8 7 12 6 0.03b
Poor3 44 6 32 4 2 0.01c
Tumor size (cm)
<5.0 41 6 23 5 7 0.96
>5.0 39 8 16 12 3
Depth of wall invasion
Mucosa, submucosa1 6 2 1 2 1 0.45a
Muscularis propria2 1 8 68 40 0 . 3 3 b
Subserosa, serosa3 56 10 34 6 6 0.72c
Stage
I  +  I I 1 9 27 55 0 . 0 4
III + IV 61 12 32 12 5
Microscopic subtypes
Intestinal1 57 10 29 11 7 0.87a
Diffuse2 1 8 48 42 0 . 2 6 b
Atypical3 5 0 2 2 1 0.21c
Lymph node metastasis
Yes 64 11 35 11 7 0.16
N o 1 6 34 63
aP: 1 VS 2; bP: 2 VS 3; cP: 1 VS 3.BMC Cancer 2008, 8:261 http://www.biomedcentral.com/1471-2407/8/261
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technology and EST virtual Northern blot were based on
DNA sequencing and were thought to be reliable methods
in gene expression evaluation. Combining multiple data-
base and analytical approaches mentioned above, the
possibility of artifacts would be greatly reduced. In the
present study, 5 S100 genes were demonstrated to be
upregulated in gastric cancer by combining analysis,
among which 4 genes were reported previously, indicating
the validity of in silico analysis strategy we used in this
work and the possibly important role of S100 genes in
development and progression of gastric cancer.
In recent years, many S100 family members have been
shown to be differentially regulated in diverse malignan-
cies. Although the action mechanisms of S100s and the
functional implications of their altered expression
remained to be determined, several studies have demon-
strated that overexpression of S100 proteins shows great
clinical implications for the diagnosis and staging of
human tumors, as well as for the prediction of prognosis.
It has been reported that S100A2 was highly expressed in
non-small cell lung cancer, esophageal squamous cell car-
cinoma, laryngeal squamous cell carcinoma, ovarian
serous papillary carcinomas, as well as gastric cancer.
S100A2 was also shown to be a predictor of distant metas-
tasis and survival rate in early-stage non-small cell lung
cancer[16]. S100A4 was found to be overexpressed in
bladder cancer and could be served as a predictor of tumor
progression [17]. Many studies have showed that S100A7
had an increased expression in breast cancer. The overex-
pression of S100A7 was related to higher TNM stages of
breast cancer and in estrogen receptor-negative invasive
breast cancers, S100A7 expression was associated with
poor outcome [18]. S100A7 overexpression was also asso-
ciated with increased malignancy of breast cancer, which
may occur through stimulation of Jab1 activity. In addi-
tion, S100A10 was identified as an upregulated gene in
squamous non-small cell lung cancers and esophageal
squamous cell carcinoma by microarray technology. All
these 4 S100 genes were also shown to be upregulaetd in
gastric cancers previously [9,10], which was further con-
firmed in the present work.
S100 genes may be downregulated in some other cancers.
For example, S100A6 was lowly expressed in prostate can-
cers, which might be related to promoter hypermethyla-
tion of S100A6. Another example is S100A2. It had a
reduced expression in prostate and oral cancer and was
regarded as a potential tumor suppressor. S100A2 can
interact with C terminus of p53 and then enhance the
transcriptional activity of p53. This cell cycle-dependent
p53-S100A2 interaction might mediate the inhibiting
effect of S100A2 on cancer. These results suggested that
S100 genes might play different roles during development
of different cancers.
S100A3, a protein correlated with the development of hair
follicle, had been proven to be overexpressed in tumors.
For example, the levels of expression of the S100A3 pro-
teins differed markedly in the astrocytic tumour tissue in
relation to the tumour types and grades[19]. The present
work confirmed for the first time that S100A3 was upreg-
ulated in gastric cancer and associated with the poor dif-
ferentiation and higher TNM stage of gastric cancer cells.
However, the role of S100A3 in differentiation and pro-
gression of gastric cancer needed to be further investi-
gated.
Conclusion
Our work suggested that in silico analysis is a valid strat-
egy for discovering differentially expressed genes in gastric
cancer, and S100A3 was a novel overexpressed gene in
gastric cancer cells and might play an important role dur-
ing the differentiation and progression of gastric cancer.
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